Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd. He was the Head of Clinical Development and was the Head of Safety Assessment at Sigma-Tau Research Inc-leading Italian Pharmaceutical Company, He was the vice president at the Quintiles Transnational Corp., the world’s largest clinical CRO, and Chairman of Quintiles Medical Development (Shanghai)Company Ltd. Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and a consultant for the China Food and Drug Administration (CFDA) and the Chinese Academy of Medical Sciences and Peking Union Medical College. He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He is a member of ICH E19 Expert Working Group, a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. Dr. Zhang was the former board of directors for the Sino-American Pharmaceutical Association (SAPA) and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is also a senior executive for the government relationship committee of Bayhelix.
